Infect Chemother.  2013 Sep;45(3):343-345. 10.3947/ic.2013.45.3.343.

Prevention of Neonatal Group B Streptococcal Disease

• Park SE

• KMID: 2170436
• DOI: http://doi.org/10.3947/ic.2013.45.3.343

Abstract

No abstract available.

Reference

1. Edmond KM, Kortsalioudaki C, Scott S, Schrag SJ, Zaidi AK, Cousens S, Heath PT. Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet. 2012; 379:547–556.

2. Zangwill KM, Schuchat A, Wenger JD. Group B streptococcal disease in the United States, 1990: report from a multistate active surveillance system. MMWR CDC Surveill Summ. 1992; 41:25–32.

3. Heath PT, Balfour G, Weisner AM, Efstratiou A, Lamagni TL, Tighe H, O'Connell LA, Cafferkey M, Verlander NQ, Nicoll A, McCartney AC. PHLS Group B Streptococcus Working Group. Group B streptococcal disease in UK and Irish infants younger than 90 days. Lancet. 2004; 363:292–294.

4. Isaacs D, Royle JA. Australasian Study Group for Neonatal Infections. Intrapartum antibiotics and early onset neonatal sepsis caused by group B Streptococcus and by other organisms in Australia. Pediatr Infect Dis J. 1999; 18:524–528.

5. Park KH, Kim KH, Kang JH, Kim KN, Kim DS, Kim YK, Kim JS, Kim JH, Kim CH, Kim HM, Oh SH, Chung EH, Cha SH, Choi YY, Hur JK, Hong YJ, Park SE, Lee HJ. Current status and clinical presentations of invasive neonatal Group B streptococcal infections in Korea. Pediatr Int. 2011; 53:236–239.

6. Schrag SJ, Zywicki S, Farley MM, Reingold AL, Harrison LH, Lefkowitz LB, Hadler JL, Danila R, Cieslak PR, Schuchat A. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med. 2000; 342:15–20.

7. Daley AJ, Isaacs D. Australasian Study Group for Neonatal Infections. Ten-year study on the effect of intrapartum antibiotic prophylaxis on early onset group B streptococcal and Escherichia coli neonatal sepsis in Australasia. Pediatr Infect Dis J. 2004; 23:630–634.

8. Kim KA, Shin SM, Choi JH. A nationwide survey on the causative organism of neonatal sepsis in Korea. J Korean Pediatr Soc. 2002; 45:55–63.

9. Choi CW. Neonatal group B streptococcal disease. Korean J Perinatol. 2012; 23:133–142.

10. Maione D, Margarit I, Rinaudo CD, Masignani V, Mora M, Scarselli M, Tettelin H, Brettoni C, Iacobini ET, Rosini R, D'Agostino N, Miorin L, Buccato S, Mariani M, Galli G, Nogarotto R, Nardi-Dei V, Vegni F, Fraser C, Mancuso G, Teti G, Madoff LC, Paoletti LC, Rappuoli R, Kasper DL, Telford JL, Grandi G. Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science. 2005; 309:148–150.

11. Lancefield RC. Two serological types of group B streptococci with related, but not identical, type-specific substances. J Exp Med. 1938; 67:25–40.

12. Baker CJ, Paoletti LC, Wessels MR, Guttormsen HK, Rench MA, Hickman ME, Kasper DL. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J Infect Dis. 1999; 179:142–150.

13. Baker CJ, Paoletti LC, Rench MA, Guttormsen HK, Carey VJ, Hickman ME, Kasper DL. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women. J Infect Dis. 2000; 182:1129–1138.

14. Baker CJ, Rench MA, McInnes P. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine. 2003; 21:3468–3472.